# Nitric Oxide During Bypass for Arterial Switch Operation

Study · id `cardio:ct-nct03661385` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03661385](<https://clinicaltrials.gov/study/NCT03661385>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03661385

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT03661385. Randomized; quadruple masking; primary purpose prevention. Start 2018-07-11 (actual); primary completion 2022-03-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT03661385, source copy `cardio:ctgov-nct03661385-2024-04-18`, retrieved 2026-10-26)
- Started: 2018-07-11 (actual) (ClinicalTrials.gov record NCT03661385, source copy `cardio:ctgov-nct03661385-2024-04-18`, retrieved 2026-10-26)
- Primary completion: 2022-03-23 (actual) (ClinicalTrials.gov record NCT03661385, source copy `cardio:ctgov-nct03661385-2024-04-18`, retrieved 2026-10-26)
- Completion: 2023-04-23 (actual) (ClinicalTrials.gov record NCT03661385, source copy `cardio:ctgov-nct03661385-2024-04-18`, retrieved 2026-10-26)
- Countries: Australia; Canada; Indonesia; Malaysia (ClinicalTrials.gov record NCT03661385, source copy `cardio:ctgov-nct03661385-2024-04-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03661385-2024-04-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Nitric Oxide During Bypass for Arterial Switch Operation
- Acronym: NASO
- Condition: Low Cardiac Output Syndrome
- Condition: Transposition of Great Vessels
- Intervention (Drug): Nitric Oxide
- Lead sponsor: Murdoch Childrens Research Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Murdoch Childrens Research Institute (`cardio:org-murdoch-childrens-research-institute`)

## Provenance

Content hash: a380e12dbc46f91e5be3121996fe28fe405d0b199dd0e2a76559069920cfc6fa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
